Search Results - "Gane, Edward J"

Future anti‐HBV strategies by Gane, Edward J.

“…Although current oral antivirals can maintain viral suppression and reduce the risk of liver‐related complications, lifelong therapy is associated with high…”
Get full text

Current perspectives on the tumor microenvironment in hepatocellular carcinoma by Santhakumar, Cositha, Gane, Edward J., Liu, Ken, McCaughan, Geoffrey W.

“…Hepatocellular carcinoma (HCC) is a heterogeneous inflammation-driven malignancy, which, despite significant advances in management, continues to portend a…”
Get full text

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial by Manns, Michael, Prof, Samuel, Didier, Prof, Gane, Edward J, Prof, Mutimer, David, Prof, McCaughan, Geoff, Prof, Buti, Maria, Prof, Prieto, MartÍn, MD, Calleja, José Luis, MD, Peck-Radosavljevic, Markus, Prof, Müllhaupt, Beat, Prof, Agarwal, Kosh, MD, Angus, Peter, Prof, Yoshida, Eric M, MD, Colombo, Massimo, Prof, Rizzetto, Mario, Prof, Dvory-Sobol, Hadas, PhD, Denning, Jill, MA, Arterburn, Sarah, MS, Pang, Phillip S, MD, Brainard, Diana, MD, McHutchison, John G, MD, Dufour, Jean-François, MD, Van Vlierberghe, Hans, Prof, van Hoek, Bart, Prof, Forns, Xavier, MD

“…Summary Background Treatment options are limited for patients infected by hepatitis C virus (HCV) with advanced liver disease. We assessed the safety and…”
Get full text

Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection by Gane, Edward J, Stedman, Catherine A, Hyland, Robert H, Ding, Xiao, Svarovskaia, Evguenia, Subramanian, G. Mani, Symonds, William T, McHutchison, John G, Pang, Phillip S

“…Background & Aims We evaluated an all-oral regimen comprising the nucleotide polymerase inhibitor sofosbuvir (SOF) with the NS5A inhibitor ledipasvir (LDV) or…”
Get full text

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection by Agarwal, Kosh, Fung, Scott K, Nguyen, Tuan T, Cheng, Wendy, Sicard, Eric, Ryder, Stephen D, Flaherty, John F, Lawson, Eileen, Zhao, Sally, Subramanian, G. Mani, McHutchison, John G, Gane, Edward J, Foster, Graham R

“…Background & Aims Tenofovir alafenamide, a phosphonate prodrug of tenofovir with greater plasma stability than tenofovir disoproxil fumarate, provides…”
Get full text

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir by Wyles, David, Dvory-Sobol, Hadas, Svarovskaia, Evguenia S, Doehle, Brian P, Martin, Ross, Afdhal, Nezam H, Kowdley, Kris V, Lawitz, Eric, Brainard, Diana M, Miller, Michael D, Mo, Hongmei, Gane, Edward J

“…Graphical abstract…”
Get full text

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial by Gane, Edward J, Dr, Roberts, Stuart K, MD, Stedman, Catherine AM, MD, Angus, Peter W, Prof, Ritchie, Brett, MD, Elston, Rob, PhD, Ipe, David, MS, Morcos, Peter N, PharmD, Baher, Linda, BS, Najera, Isabel, PhD, Chu, Tom, MD, Lopatin, Uri, MD, Berrey, M Michelle, MD, Bradford, William, MD, Laughlin, Mark, MD, Shulman, Nancy S, MD, Smith, Patrick F, PharmD

“…Summary Background Present interferon-based standard of care treatment for chronic hepatitis C virus (HCV) infection is limited by both efficacy and…”
Get full text

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients by Gane, Edward J., Weilert, Frank, Orr, David W., Keogh, Geraldine F., Gibson, Michael, Lockhart, Michelle M., Frampton, Christopher M., Taylor, Kenneth M., Smith, Robin A. J., Murphy, Michael P.

“…Background: Increased oxidative stress and subsequent mitochondrial damage are important pathways for liver damage in chronic hepatitis C virus (HCV)…”
Get full text

Perioperative immunonutrition in patients undergoing liver transplantation: A randomized double‐blind trial by Plank, Lindsay D., Mathur, Sachin, Gane, Edward J., Peng, Sze‐Lin, Gillanders, Lyn K., McIlroy, Kerry, Chavez, Carolina Paras, Calder, Philip C., McCall, John L.

“…Preliminary work suggested that perioperative immunonutrition (IMN) enriched in n‐3 fatty acids, arginine, and nucleotides may improve preoperative nutritional…”
Get full text

Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation by Gane, Edward J, Angus, Peter W, Strasser, Simone, Crawford, Darrell H.G, Ring, John, Jeffrey, Gary P, McCaughan, Geoffrey W

“…Background & Aims: High-dose intravenous hepatitis B immunoglobulin (HBIG) may prevent recurrent hepatitis B virus (HBV) infection, but the cost has limited…”
Get full text

Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen–positive liver transplant candidates by Gane, Edward J., Patterson, Scott, Strasser, Simone I., McCaughan, Geoffrey W., Angus, Peter W.

“…Without effective prophylaxis, liver transplantation for hepatitis B virus (HBV)–related liver disease is frequently complicated by severe and rapidly…”
Get full text

Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV by Pan, Calvin Q, Chang, Ting-Tsung, Bae, Si Hyun, Brunetto, Maurizia, Seto, Wai-Kay, Coffin, Carla S, Tan, Susanna K, Mo, Shuyuan, Flaherty, John F, Gaggar, Anuj, Nguyen, Mindie H, Çelen, Mustafa Kemal, Thompson, Alexander, Gane, Edward J

“…Use of tenofovir disoproxil fumarate (TDF) improves patient outcomes in preventing mother-to-child transmission (pMTCT) of the hepatitis B virus (HBV) in…”
Get full text

Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B by Keeffe, Emmet B, Zeuzem, Stefan, Koff, Raymond S, Dieterich, Douglas T, Esteban–Mur, Rafael, Gane, Edward J, Jacobson, Ira M, Lim, Seng G, Naoumov, Nikolai, Marcellin, Patrick, Piratvisuth, Teerha, Zoulim, Fabien

“…An international group of experienced hepatologists and virologists conducted a single-day workshop to review the management of patients with chronic hepatitis…”
Get full text

The natural history of recurrent hepatitis C and what influences this by Gane, Edward J.

“…Key Points 1 Liver failure and liver cancer from chronic hepatitis C are the most common indications for liver transplantation and numbers of both are…”
Get full text

Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B by Yuen, Man‐Fung, Berliba, Elina, Sukeepaisarnjaroen, Wattana, Ahn, Sang Hoon, Tanwandee, Tawesak, Lim, Young‐Suk, Kim, Yoon Jun, Poovorawan, Kittiyod, Tangkijvanich, Pisit, Schwabe, Christian, Eley, Timothy, Brown, Joanne, Lee, Amy C. H., Thi, Emily P., Paratala, Bhavna, Mani, Nagraj, Sofia, Michael J., Picchio, Gaston, Sims, Karen D., Gane, Edward J.

“…AB‐506 is a potent, pan‐genotypic small molecule capsid inhibitor that inhibits hepatitis B virus (HBV) pregenomic RNA encapsidation. We assessed the safety,…”
Get full text

Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders by GANE, Edward J, ROUZIER, Régine, KULKARNI, Rohit, YING ZHANG, SMITH, Patrick, YETZER, Ellen S, SHULMAN, Nancy S, WIERCINSKA-DRAPALO, Alicja, LARREY, Dominique G, MORCOS, Peter N, BRENNAN, Barbara J, LE POGAM, Sophie, NAJERA, Isabel, PETRIC, Rosemary, TRAN, Jonathan Q

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection by Asselah, Tarik, Zeuzem, Stefan, Soriano, Vicente, Bronowicki, Jean-Pierre, Lohse, Ansgar W, Müllhaupt, Beat, Schuchmann, Marcus, Bourlière, Marc, Buti, Maria, Roberts, Stuart K, Gane, Edward J, Stern, Jerry O, Voss, Florian, Baum, Patrick, Gallivan, John-Paul, Böcher, Wulf O, Mensa, Federico J

“…Whether inosine triphosphatase (ITPA) gene polymorphisms predict anemia during interferon-free therapy in chronic hepatitis C virus (HCV)-infected patients is…”
Get full text

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study by Gane, Edward J, DeJesus, Edwin, Janczewska, Ewa, George, Jacob, Diago, Moises, Da Silva, Mariliza Hendrique, Reesink, Henk, Nikitin, Igor, Hinrichsen, Holger, Bourgeois, Stefan, Ferenci, Peter, Shukla, Umesh, Kalmeijer, Ronald, Lenz, Oliver, Fevery, Bart, Corbett, Chris, Beumont, Maria, Jessner, Wolfgang

“…This Phase 3, open-label, rollover study (NCT01323244) investigated the efficacy and safety of simeprevir plus peginterferon α-2a (PegIFNα-2a) and ribavirin…”
Get full text

The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment by Gane, Edward J., Metivier, Sophie, Nahass, Ronald, Ryan, Michael, Stedman, Catherine A., Svarovskaia, Evguenia S., Mo, Hongmei, Doehle, Brian, Dvory‐Sobol, Hadas, Hedskog, Charlotte, Lin, Ming, Brainard, Diana M., Yang, Jenny C., McHutchison, John G., Sulkowski, Mark, Younes, Ziad, Lawitz, Eric

“…S282T in NS5B is the primary amino acid substitution associated with resistance to sofosbuvir (SOF) but has rarely been detected in patients treated with a…”
Get full text

Is hepatitis B immune globulin still needed after liver transplantation for chronic hepatitis B? by Gane, Edward J.

Get full text